EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn’s disease

Bin Liu, Daoli Liu, Chongbin Qi, Caroline Sunggip iD

Postgraduate Medical Journal · 2025

DOI: 10.1093/postmj/qgaf172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2025. Verfasst von Bin Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Anqing First People's Hospital Affiliated to Anhui Medical University, 187 Huazhong Road, Anqing 246000, Anhu…. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Inflammation, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Special Research Project for the Affiliated Teaching Hospitals of Wannan Medical College, Anhui Provincial Scientific Research Project for Higher Education Institutions, Anhui Province Health Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It remains unclear whether pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) can predict treatment outcomes in Crohn’s disease (CD) patients receiving infliximab. This study explored the role of PIV and SII in predicting treatment response and prognosis in CD patients receiving biologics.

Methods

Clinical data of 160 patients with CD were retrospectively collected from Anqing First People’s Hospital in China. Patients were classified into effective and ineffective groups based on therapeutic response. Additionally, 60 healthy controls were enrolled. Serum levels of PIV and SII were measured in all participants. The effectiveness of infliximab was evaluated based on Crohn’s Disease Activity Index. Clinical remission was defined as a Crohn’s Disease Activity Index score <150, while a reduction of ≥70 points from baseline indicated clinical response.

Results

The effective group included 125 patients (mean age, 34.5 ± 10.2 years; 68 men [54.4%]), and the ineffective group included 35 patients (mean age, 36.1 ± 9.8 years; 18 men [51.4%]). The healthy control group covered 60 individuals (mean age, 33.8 ± 11.1 years; 32 men [53.3%]). Patients in the high SII group demonstrated a markedly elevated hazard ratio (HR = 20.786, P < .001). A higher PIV was associated with better prognosis (HR = 0.386, 95% confidence interval: 0.228–1.655, P = .011). Conversely, a higher SII was associated with worse prognosis (HR = 20.786, 95% confidence interval: 9.412–45.902, P < .001).

Conclusions

Both PIV and the SII are useful in predicting efficacy of CD patients treated with biologics. Compared with SII, PIV is a better choice. Key messages What is already known on this topic: Infliximab is the most efficacious and widely used biologic for inducing remission in moderate-to-severe Crohn’s disease. SII and PIV have been validated as prognostic indicators in many diseases. What this study adds: Higher PIV and SII both have positive effects on predicting the prognosis of patients with Crohn’s disease. Compared with the SII, the PIV holds greater significance in predicting the clinical outcomes for patients with Crohn’s disease. How this study might affect research, practice or policy: PIV and SII may aid in risk stratification and individualized treatment planning in Crohn’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabInflammationGastrointestinal AgentsHumansMaleFemaleAdultRetrospective StudiesTreatment OutcomeSeverity of Illness IndexPrognosisBiomarkersChinaMiddle AgedCase-Control Studies

Stichwörter der Autor:innen

Crohn’s diseasebiological agentsclinical efficacypan-immune-inflammation valuesystemic immune-inflammation index

Substanzen

InfliximabGastrointestinal AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Anqing First People's Hospital Affiliated to Anhui Medical University, 187 Huazhong Road, Anqing 246000, Anhui Province, China.
  • Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Jalan UMS, Kota Kinabalu 88400, Sabah, Malaysia.

ORCID-Profile: Caroline Sunggip

Förderung

  • Special Research Project for the Affiliated Teaching Hospitals of Wannan Medical College
  • Anhui Provincial Scientific Research Project for Higher Education Institutions
  • Anhui Province Health Research Project

Zitieren

APA

Liu, B., Liu, D., Qi, C., & Sunggip, C. (2025). Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn’s disease. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf172

Vancouver

Liu B, Liu D, Qi C, Sunggip C. Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn’s disease. Postgraduate Medical Journal. 2025. doi:10.1093/postmj/qgaf172

BibTeX
@article{Liu2025,
  author = {Liu, Bin and Liu, Daoli and Qi, Chongbin and Sunggip, Caroline},
  title = {Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn’s disease},
  journal = {Postgraduate Medical Journal},
  year = {2025},
  doi = {10.1093/postmj/qgaf172}
}
Kostenlos starten →